Scholarlink

<p>Colorectal cancer (CRC) is a third leading cause of death and is often recognised by a higher mutation burden. The standard clinical regimen for CRC chiefly focuses on targeting a single-cell death mechanism, which encounters constraints such as resistance, chronic toxicity, and suboptimal efficacy. Thus, triggering a hybrid cell death mechanism that acts through distinct pathways offers a promising avenue in CRC management. The present investigation explores the combined therapy of Sorafenib (SOR) and Atorvastatin (ATST) to induce a dual cell death mechanism, specifically ferroptosis and classic apoptosis, in colon cancer cells. The combination of ATST + SOR at a 1:1 ratio showed a combination index value of &lt; 1 and a dose reduction index &gt; 1 in HT29, HCT116, CT26, and SW480 cell lines. <i>In-vitro</i> studies with a synergistic combination of ATST + SOR showed amplified levels of MDA, ROS, and membrane depolarisation, while diminishing antioxidant levels. The cell migration, cell-invasion, and wound healing assays revealed the anti-metastatic potential of the combination. <i>In-vivo</i> efficacy study revealed marked reduction in disease manifestations with tumor growth inhibition rate of ~ 80%. Unfortunately, the toxicity study revealed the presence of systemic, organ, and hemolytic toxicity. In a nutshell, the proposed combination of ATST and SOR presents a compelling strategy to trigger a dual cell death mechanism, thereby amplifying the efficacy and anti-metastatic potential in CRC. Nonetheless, the safety concerns warrant continued investigation into advanced drug delivery systems to boost efficacy and clinical usage of the present combination.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring Synergistic Potential of Sorafenib and Atorvastatin to Launch Apoptosis and Ferroptosis-driven Mixed Cell Death Mechanism in Colorectal Cancer

  • 期刊论文

  • 发表日期：

    2026年5月27日

查看全文
  • Vivek Yadav,
  • Sayali Dighe,
  • Pratik Dhake,
  • Sanyog Jain

摘要

Colorectal cancer (CRC) is a third leading cause of death and is often recognised by a higher mutation burden. The standard clinical regimen for CRC chiefly focuses on targeting a single-cell death mechanism, which encounters constraints such as resistance, chronic toxicity, and suboptimal efficacy. Thus, triggering a hybrid cell death mechanism that acts through distinct pathways offers a promising avenue in CRC management. The present investigation explores the combined therapy of Sorafenib (SOR) and Atorvastatin (ATST) to induce a dual cell death mechanism, specifically ferroptosis and classic apoptosis, in colon cancer cells. The combination of ATST + SOR at a 1:1 ratio showed a combination index value of < 1 and a dose reduction index > 1 in HT29, HCT116, CT26, and SW480 cell lines. In-vitro studies with a synergistic combination of ATST + SOR showed amplified levels of MDA, ROS, and membrane depolarisation, while diminishing antioxidant levels. The cell migration, cell-invasion, and wound healing assays revealed the anti-metastatic potential of the combination. In-vivo efficacy study revealed marked reduction in disease manifestations with tumor growth inhibition rate of ~ 80%. Unfortunately, the toxicity study revealed the presence of systemic, organ, and hemolytic toxicity. In a nutshell, the proposed combination of ATST and SOR presents a compelling strategy to trigger a dual cell death mechanism, thereby amplifying the efficacy and anti-metastatic potential in CRC. Nonetheless, the safety concerns warrant continued investigation into advanced drug delivery systems to boost efficacy and clinical usage of the present combination.

Graphical Abstract